| Phase 3 |
| NCT04824092 |
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate… |
Diffuse Large B-cell Lymphoma |
Active, Not Recruiting |
| NCT05429268 |
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in… |
Large B-Cell Lymphoma |
Active, Not Recruiting |
| Phase 2 |
| NCT06760156 |
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym |
Large B-cell Lymphoma |
Recruiting |
| NCT05786040 |
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative… |
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder |
Recruiting |
| NCT05615636 |
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients… |
Hodgkin Lymphoma |
Recruiting |
| NCT07502872 |
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse… |
Diffuse Large B Cell Lymphoma |
Not Yet Recruiting |
| NCT04646395 |
Study of Acalabrutinib and Tafasitamab in MZL Patients |
Marginal Zone Lymphoma |
Active, Not Recruiting |
| NCT04978584 |
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination… |
Diffuse Large B-Cell Lymphoma |
Active, Not Recruiting |
| NCT05718869 |
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic… |
Chronic Lymphocytic Leukemia |
Active, Not Recruiting |
| NCT05453500 |
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of… |
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative |
Active, Not Recruiting |
| NCT07582159 |
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic… |
Chronic Lymphocytic Leukemia |
Not Yet Recruiting |
| NCT07585747 |
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and… |
Follicular Lymphoma |
Not Yet Recruiting |
| NCT04974216 |
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large… |
DLBCL |
Active, Not Recruiting |
| Phase 1/2 |
| NCT05366218 |
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage… |
ALL, Childhood B-Cell |
Recruiting |
| NCT06434363 |
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy… |
Autoimmune Disorders |
Recruiting |
| NCT05222555 |
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined… |
Diffuse Large B Cell Lymphoma |
Active, Not Recruiting |
| NCT03930953 |
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With… |
Lymphoma, Non-Hodgkin |
Active, Not Recruiting |
| NCT04661007 |
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other… |
Non Hodgkins Lymphoma |
Active, Not Recruiting |
| Early Phase 1 |
| NCT04161248 |
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or… |
Lymphoma, B-Cell |
Active, Not Recruiting |